13 completed, 5 unknown, 2 recruiting, 1 active not recruiting. 24 Phase 2, 5 Phase 1, 3 Phase 3.
Follow Progressive Supranuclear Palsy: new trials by email Literature Review of Progressive Supranuclear Palsy trials Research Report on Progressive Supranuclear Palsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies ARO-MAPT-SC, Placebo - Alzheimer Disease, Tauopathies | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 160 | 2025-11-18 | 2026-11-10 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) FNP-223, Placebo - Progressive Supranuclear Palsy | Phase 2 | Active not recruiting | Ferrer Internacional S.A. | 241 | 2024-07-23 | 2025-10-15 |
| The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism Nicotinamide Riboside, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Recruiting | Haukeland University Hospital | 330 | 2024-03-05 | 2025-01-10 |
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 GV1001 Placebo, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 67 | 2023-12-12 | 2025-11-21 |
| GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 78 | 2023-06-14 | 2026-02-10 |
| A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day - Progressive Supranuclear Palsy | Phase 2 | Completed | Transposon Therapeutics, Inc. | 42 | 2021-12-12 | 2026-04-08 |
| Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Droxidopa, Placebo Oral Tablet - Parkinson Disease, Multiple System Atrophy | Phase 2 | Withdrawn | Loma Linda University | 2021-12-01 | 2022-03-02 | |
| RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY RT001, Placebo - Progressive Supranuclear Palsy | Phase 2 | Unknown | Biojiva LLC | 40 | 2021-06-23 | 2021-06-25 |
| Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 Fasudil - Progressive Supranuclear Palsy, Corticobasal Syndrome | Phase 2 | Unknown | Woolsey Pharmaceuticals | 15 | 2021-01-22 | 2022-06-03 |
| Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Tolfenamic Acid, Placebos - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Unknown | NeuroTau, Inc. | 24 | 2021-01-01 | 2020-02-05 |
| A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP AZP2006 oral solution, Placebo oral solution - Progressive Supranuclear Palsy | Phase 2 | Completed | AlzProtect SAS | 36 | 2020-06-22 | 2025-03-17 |
| Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) NBMI, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Completed | EmeraMed | 20 | 2019-09-16 | 2021-09-23 |
| A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) Placebo, ABBV-8E12 - Progressive Supranuclear Palsy | Phase 2 | Terminated | AbbVie | 378 | 2016-12-12 | 2021-02-03 |
| Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism stem cell therapy - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 25 | 2012-12-01 | 2013-04-04 |
| Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Davunetide, Placebo - Progressive Supranuclear Palsy | Phase 2 / Phase 3 | Completed | Allon Therapeutics | 313 | 2010-10-01 | 2013-01-17 |
| Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy alpha-lipoic acid and L-acetyl carnitine - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 11 | 2010-09-14 | 2017-05-30 |
| A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Lithium - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 1 / Phase 2 | Completed | Westat | 17 | 2008-09-01 | 2024-05-17 |
| Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy rivastigmine - Progressive Supranuclear Palsy, Dementia | Phase 2 | Unknown | University Hospital Tuebingen | 20 | 2008-02-01 | 2008-02-18 |
Showing 20 of 24. Sign in to see all of them.
Supranuclear Palsy, Progressive (24) · Corticobasal Degeneration (4) · Multiple System Atrophy (3) · Tauopathies (3) · Neurodegenerative Diseases (2) · Pick Disease of the Brain (2) · Alzheimer Disease (1) · Dementia (1) · Disease Progression (1) · Fatigue (1) · Frontotemporal Dementia (1) · Frontotemporal Lobar Degeneration (1) · Nerve Degeneration (1) · Nervous System Diseases (1) · Parkinson Disease (1)
Basal Ganglia Diseases (24) · Brain Diseases (24) · Central Nervous System Diseases (24) · Cranial Nerve Diseases (24) · Eye Diseases (24) · Movement Disorders (24) · Neurologic Manifestations (24) · Ocular Motility Disorders (24) · Ophthalmoplegia (24) · Paralysis (24) · Pathological Conditions, Signs and Symptoms (24) · Signs and Symptoms (24) · Nervous System Diseases (23) · Neurodegenerative Diseases (22) · Tauopathies (21)
Saline Solution (2) · coenzyme Q10 (2) · Acetylcarnitine (1) · Droxidopa (1) · Glial Cell Line-Derived Neurotrophic Factor (1) · Lithium (1) · RT001 (1) · Rivastigmine (1) · Safflower Oil (1) · Thioctic Acid (1) · Valproic Acid (1) · davunetide (1) · fasudil (1) · nicotinamide-beta-riboside (1) · sodium phenylbutyrate and taurursodiol (1)
GemVax & Kael (2) · AbbVie (1) · Allon Therapeutics (1) · AlzProtect SAS (1) · Amylyx Pharmaceuticals Inc. (1) · Arrowhead Pharmaceuticals (1) · Biojiva LLC (1) · EmeraMed (1) · Ferrer Internacional S.A. (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · German Parkinson Study Group (GPS) (1) · Haukeland University Hospital (1) · Lahey Clinic (1) · Loma Linda University (1) · Nantes University Hospital (1)
United States (12) · Germany (7) · France (6) · Italy (4) · Canada (3) · Spain (3) · United Kingdom (3) · Australia (2) · South Korea (2) · Hungary (1) · Japan (1) · New Zealand (1) · Norway (1) · Poland (1) · Portugal (1)
Sang Jae Kim (2) · Adam Boxer, M.D., PhD. (1) · Charalampos Tzoulis, MD, PhD (1) · Claire Henchcliffe, MD DPhil (1) · Daniela Berg, Doctor (1) · Diana Apetauerova, MD (1) · Khashayar Dashtipour, M.D. Ph.D. (1) · Marwan Sabbagh, MD (1) · Nasser Zawia, PhD (1) · Pascal Derkinderen (1) · Peter Ljubenkov, MD (1) · Philippe Verwaerde, PhD (1) · Rosaria Giordano, MD (1)
PMID 24438512, PMID 24873720, PMID 27136096, PMID 27160012, PMID 28436538, PMID 33609476, PMID 34712113, PMID 38825840, PMID 40368603, PMID 41239890
2016 (1), 2023 (1)